Notice of Correction to Eligibility Criteria for RFA-HL-23-007 Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)
Notice Number:
NOT-HL-23-100

Key Dates

Release Date:

July 20, 2023

Related Announcements

  • March 14, 2022 - Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed). See NOFO RFA-HL-23-007.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this notice is to inform applicants of a correction to the Eligibility Criteria for RFA-HL-23-007 Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed), issued on March 14, 2022. The next Application Due Date is October 13, 2023, and the Expiration Date is January 11, 2025. Changes to the NOFO are shown below. 

Currently Reads:

Section III. Eligibility Information

1. Eligible Applicants
Only fellowship programs recognized by the Accreditation Council for Graduate Medical Education (ACGME) may be included in the proposed program. For Dental Specialty postgraduate programs, only dental specialties approved by the Council on Dental Education and Licensure of the American Dental Association may be included in the proposed program. For veterinary specialties, only veterinary specialties approved by the American Veterinary Medical Association may be included in the proposed program.

 Modified to Read (in bold italics):

Section III. Eligibility Information

1. Eligible Applicants
Fellowship programs recognized by the Accreditation Council for Graduate Medical Education (ACGME) or other relevant accrediting organization may be included in the proposed program. For Dental Specialty postgraduate programs, only dental specialties approved by the Council on Dental Education and Licensure of the American Dental Association may be included in the proposed program. For veterinary specialties, only veterinary specialties approved by the American Veterinary Medical Association may be included in the proposed program.

All other aspects of this NOFO remain unchanged.

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)

David Schopfer, M.D.
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-402-3833
Email: david.schopfer@nih.gov